Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)

NCT00506259 is registered in ClinicalTrials.gov with National Human Genome Research Institute (NHGRI) as lead sponsor.

NCT NCT00506259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00506259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase One Treatment Trial of the Circadian Sleep Disturbance in Smith-Magenis Syndrome (SMS)
Lead sponsor
National Human Genome Research Institute (NHGRI)
Phase
Phase 1
Overall status
Completed
Start date
July 17, 2007
Completion date
May 22, 2018
Enrollment
23 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chromosome deletion, developmental delay disorders, mental retardation, self injurious behavior, sleep disorders, circadian rhythm